IVXpress
Latest round
- Series F
Last raised
- Sep 2021
Total raised
- $166M
Investors
- 6
About IVXpress
, provides biologic injections and infusions for patients with chronic conditions. The company has approximately 50 infusion centers across 16 markets as of 2021. In September 2021, IVXpress, Inc. IVXpress, Inc. works with adult and pediatric patients with chronic conditions such as multiple sclerosis, Crohn’s disease, rheumatoid arthritis, osteoporosis, pediatric and adult immunotherapy, vitamin and mineral deficiencies, and immune system disorders to provide hospital-based infusion and injection therapy through local centers. will accelerate its entry into new markets in 2022 and realize its vision of becoming the preferred destination for pharmaceutical care for patients with complex chronic conditions.
Who invested in IVXpress
6 investors across 4 rounds
See all investors in IVXpress
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about IVXpress
Who invested in IVXpress?
IVXpress has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has IVXpress raised?
IVXpress has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did IVXpress last raise money?
IVXpress's most recent round on record is a Series F, in Sep 2021.
What does IVXpress do?
, provides biologic injections and infusions for patients with chronic conditions.
Where is IVXpress headquartered?
IVXpress is headquartered in Brentwood, US.
Which VCs invest in companies like IVXpress?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at IVXpress's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series F
Raising like IVXpress? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.